HRS-5965
Unknown / undisclosed
Evidence outlook · registrational
Paroxysmal Nocturnal Hemoglobinuria: registrational trials complete
Its supporting mid-stage studies have completed. Its registrational studies have completed. Check News and the registry record for topline outcomes.
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. The complete registry, including every study not featured here, is listed below.
Featured-trial selection for this indication is pending.
All registered studies
Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.
Phase 3 (3)
What this study did
What this study did
What this study did
Phase 2 (4)
What this study did
What this study did
What this study did
What this study did
Phase 1 (7)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Competitive landscape
Other Complement Factor B drugs
Iptacopan, FWY003, ALN-CFB. Compare all 4 Complement Factor B drugs
3 other tracked programmes target this mechanism, 1 of them ahead of this one.
This drug's own stage for Paroxysmal Nocturnal Hemoglobinuria: Phase 3. Competitors below are sorted furthest-along first.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials | |
|---|---|---|---|---|---|---|
| HRS-5965: this drug | Phase 3 | Undisclosed | Complement Factor B | not yet graded | No reviewed efficacy summary in this indication | |
| Eculizumab (Soliris) | Approved | Monoclonal antibody | Complement C5 | Weak signal | Featured results are safety only in this race | |
| Iptacopan (Fabhalta) | Approved | Small molecule | Complement Factor B | Partial signal | NCT04558918: At 24 weeks, without transfusion: Hb increase of 2 g/dL or more in 51 of 60 on iptacopan vs 0 of 35 on anti-C5; Hb of 12 g/dL or more in 42 of 60 vs 0 of 35. Superiority shown on both primaries. NCT04820530: Single arm, 24 weeks: estimated 92.2% (95% CI 82.5 to 100.0) of 40 complement-inhibitor-naive patients had a sustained Hb increase of 2 g/dL or more without transfusion. No comparator. | |
| Pegcetacoplan (Empaveli) | Approved | Peptide | Complement C3 | Partial signal | NCT03500549: Least Squares (LS) Mean Change From Baseline to Week 16 in Hemoglobin (Hb) Level During the RCP (Baseline and Week 16): Pegcetacoplan to Pegcetacoplan 2.37 Grams per deciliter (g/dL) (Standard Error 0.363) | Eculizumab to Pegcetacoplan -1.47 Grams per deciliter (g/dL) (Standard Error 0.666) | |
| Ravulizumab (Ultomiris) | Approved | Monoclonal antibody | Complement C5 | not yet graded | No reviewed efficacy summary in this indication | |
| Pozelimab (Veopoz) | Phase 3 | Monoclonal antibody | Complement C5 | not yet graded | No reviewed efficacy summary in this indication | |
| FWY003 | Phase 2(overall) | Undisclosed | Complement Factor B | not yet graded(overall) | No reviewed efficacy summary in this indication | |
| Zaltenibart | Phase 2 | Monoclonal antibody | MASP-3 | Weak signal | NCT05972967: Interim (data cut-off 8 July 2024): primary endpoints were safety and tolerability; zaltenibart was well tolerated, treatment-related adverse events in 46.2% of patients (mostly mild to moderate), 1 discontinuation for a treatment-emergent serious adverse event. Hemoglobin rose from a mean baseline of 9.26 g/dL by 3.39 g/dL at day 29 and 3.27 g/dL at day 169 on add-on to ravulizumab (N=13), and by 3.85 g/dL at day 309 on monotherapy (N=6, P=0.003). | |
| ALN-CFB | Phase 1/2 | RNA / oligonucleotide | Complement Factor B | not yet graded | No reviewed efficacy summary in this indication |
Compare side by side
Upcoming events
(3 total)
Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Follow HRS-5965 to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.
Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.